Combo Product Firms Should Follow Specialty Pharma Model – Angiotech
This article was originally published in The Gray Sheet
Executive Summary
Angiotech Pharmaceuticals believes the best way to commercially exploit drug/device combination products is to act like a specialty pharmaceutical firm instead of a device company